Cytek Biosciences, Inc. (CTKB)
| Market Cap | 763.78M +24.7% |
| Revenue (ttm) | 207.65M +5.5% |
| Net Income | -81.20M |
| EPS | -0.63 |
| Shares Out | 130.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,280,258 |
| Open | 5.55 |
| Previous Close | 5.52 |
| Day's Range | 5.41 - 5.87 |
| 52-Week Range | 3.31 - 6.34 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 6.50 (+11.3%) |
| Earnings Date | Nov 4, 2026 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu... [Read more]
Financial Performance
In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 11.30% from the latest price.
News
Cytek Biosciences price target raised to $7 from $6 at Stephens
Stephens raised the firm’s price target on Cytek Biosciences (CTKB) to $7 from $6 and keeps an Overweight rating on the shares after what the firm views as “a relatively…
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discover...
Cytek Biosciences Earnings Call Transcript: Q3 2026
Q3 revenue rose 2% YoY as U.S. growth, high-end analyzer demand and service gains offset regional and product-category weakness. FY2026 revenue guidance was narrowed to $208M-$211M, with adjusted EBITDA expected around break-even.
Cytek Biosciences Earnings release: Q3 2026
Cytek Biosciences released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Cytek Biosciences Quarterly report: Q3 2026
Cytek Biosciences has published its Q3 2026 quarterly earnings report on November 4, 2026.
Cytek Biosciences Slides: Q3 2026
Cytek Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...
Cytek Biosciences price target raised to $6 from $4.75 at Stephens
Stephens raised the firm’s price target on Cytek Biosciences (CTKB) to $6 from $4.75 and keeps an Overweight rating on the shares in conjunction with the firm’s Q3 earnings preview…
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter ...
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
Cytek Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
H1 2026 saw 6% growth, led by strong U.S. and China demand, with new products like Borealis and Evo 2 driving innovation. Service and reagent businesses are expanding, while digital platforms enhance customer retention. Outlook for 2027 is optimistic, supported by product momentum and market recovery.
Sysmex Europe, Cytek Biosciences announce European collaboration
Sysmex Europe and Cytek Biosciences (CTKB) announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagn...
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
FREMONT, Calif., and HAMBURG, Germany, Sept.
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometr...
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced t...
Cytek Biosciences price target lowered to $5 from $5.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5 from $5.50 and keeps an Equal Weight rating on the shares.
Cytek Biosciences reports Q2 EPS (9c), consensus (2c)
Reports Q2 revenue $48.14M, consensus $48.61M. “Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instrument...
Cytek Biosciences sees FY26 revenue $207M-$212M, consensus $208.83M
The company said, “Cytek Biosciences (CTKB) is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint…
Cytek Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 6% year-over-year to $48.1 million, led by strong U.S. and China performance and robust service growth. New product launches and a strategic reorganization support future expansion, while full-year guidance was raised to $207–$212 million.
Cytek Biosciences Quarterly report: Q2 2026
Cytek Biosciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Cytek Biosciences Slides: Q2 2026
Cytek Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Cytek Biosciences Earnings release: Q2 2026
Cytek Biosciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Cytek Biosciences Reports Second Quarter 2026 Financial Results
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter...